Products - Head and neck cancers | Topic

Showing 12 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Head and neck cancers Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 12 products

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

Dinutuximab beta for treating neuroblastoma (TA538)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477]

Head and neck cancers Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 12 products

Guidance programme
1 selected